JAZZ Jazz Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 76

EPS in 2026 (TTM): $3.64

Last Report Period Date: Sep 30, 2026

According to the most recent financial data from September 2026, the current EPS (TTM) is $3.64. Jazz Pharmaceuticals's EPS for 2025 came in at -$5.84, marking a decrease from $9.06 in 2024. For the quarterly period ending on Sep 30, 2026, JAZZ's EPS was -$7.48.

JAZZ earnings history

Historical annual and quarterly earnings per share (EPS) data for Jazz Pharmaceuticals

EPS (TTM)

$3.64

EPS Growth YoY (Quarterly)

-280.7%

EPS (Quarterly)

-$7.48

EPS Growth (Quarterly)

-345.2%

Jazz Pharmaceuticals had an annual EPS of -$5.84, marking a decrease of 164.5% from $9.06 in 2024. The quarterly EPS for the period ending Sep 30, 2026, was -$7.48, marking a 280.7% decrease from the same quarter last year. JAZZ's TTM EPS stands at $3.64 as of September 2026. Jazz Pharmaceuticals's EPS for 2024 stood at $9.06, a 38.3% increase from 2023.

JAZZ EPS vs price chart

JAZZ EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-280.7%

EPS growth YoY

-164.5%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the last 12 months, Jazz Pharmaceuticals has registered an EPS growth of -280.7% (YoY, quarterly).

JAZZ Earnings Waterfall

Breakdown of revenue, profit and net income for Jazz Pharmaceuticals

JAZZ Earnings vs Peers

What are the earnings of JAZZ compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
NVS Novartis AG	30.53	21.8%	31.2%	15.2%
JAZZ Jazz Pharmaceuticals plc	66.04	-164.5%	N/A	N/A
TEVA Teva- Pharmaceutical Industries Ltd	97	184.8%	N/A	N/A
PRGO Perrigo Company plc	N/A	-723.2%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.